Latest News
TxCell, a biotechnology company, has reported positive immuno-monitoring results from Phase I/II study in Crohn's disease (CATS1) with...
> read more
Salix commences phase 3 study of Rifaximin drug
Salix Pharmaceuticals has begun the Phase 3 study, TARGET 3, to investigate the efficacy and safety of repeat treatment with Rifaximin (Xifaxan) 550mg TID (three times daily dosage) for 14 days...
Takeda Phase III ulcerative colitis trial meets primary endpoints
Takeda Pharmaceutical Company has announced positive top-line results from a pivotal Phase III trial of vedolizumab in patients with moderately to severely active ulcerative colitis, who...
European commission clears Plexxikon melanoma drug
Plexxikon's Zelboraf (vemurafenib) has been approved by the European Commission as a monotherapy for the treatment of adult patients with BRAFV600 mutation-positive unresectable or...
Debiopharm begins Phase Ib expansion study of Debio 0932
Swiss-based Debiopharm Group has initiated patient treatment in a Phase Ib clinical trial of Debio 0932, a heat shock protein 90 (HSP90)...
Gilead reports viral relapse in ELECTRON study patients
Viral relapse has been observed in the majority of hepatitis C genotype 1 patients with a prior "null" response to an interferon (IFN)-containing regimen in the ongoing ELECTRON study within...
Celladon concludes financing to advance Mydicar drug
Celladon Corporation has secured a $43m equity financing to advance its lead investigational product candidate MYDICAR®, designed for the treatment of heart...
Critical Pharma, Nottingham University to jointly develop intranasal formulation for osteoporosis
Critical Pharmaceuticals has teamed up with the University of Nottingham to develop a nano-enabled intranasal formulation of teriparatide, intended for the treatment of...
AiCuris reports efficacy data of Letermovir drug
AiCuris' Letermovir (AIC246) has met its primary efficacy endpoints in a Phase 2 trial for the control of human cytomegalovirus (HCMV) prophylaxis in human blood precursor cell (HBPC)...
BioCryst reports favourable preclinical data of hepatitis drug
BioCryst Pharmaceuticals has announced the positive preclinical results of its adenine nucleoside analog targeting viral RNA polymerase, BCX5191, used for the treatment of hepatitis...
Prolor Biotech Factor VIIa-CTP shows positive data in preclinical study
Prolor Biotech has announced positive top-line preclinical data from a comparative study of its longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic...
Celsion enrols first patient in ThermoDox phase II study
Celsion Corporation has enrolled the first patient in its randomised Phase II study of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, plus radiofrequency ablation (RFA),...
Santarus initiates patient enrolment in Uceris study
Santarus has commenced patient enrolment in a multicentre, randomised, double-blind, placebo-controlled Phase IIIb trial of its UCERIS (budesonide) tablets 9mg, used to treat patients with mild...
Insmed to commence patient enrolment in Arikace drug trials
Insmed is planning to commence a Phase 2 clinical trial of Arikace (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease, and an European...
Altheos doses first patient in glaucoma drug trial
Altheos has dosed the first patient in a Phase 2a clinical trial of its investigational drug candidate ATS907, a Rho kinase (ROCK)-selective inhibitor used as a next-generation eye drop...
Soligenix reports phase 1/2 trial data of SGX201
Soligenix, a development stage biopharmaceutical company, has reported the preliminary results from its Phase 1/2 clinical study of SGX201, a time-release formulation of oral...
Tekmira begins TKM-Ebola Phase 1 clinical study
Tekmira Pharmaceuticals, a developer of RNA interference (RNAi) therapeutics, has initiated patient enrollment in its Phase 1 clinical trial of...
DMC completes review of BioSante LibiGel Phase III study
The independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of BioSante Pharmaceuticals' LibiGel Phase III cardiovascular (CV) and breast cancer safety...
Avanir Pharmaceuticals reports Phase III data of AVP-923
Avanir Pharmaceuticals has reported safety and efficacy results of its AVP-923 medication in the study entitled "Efficacy and Safety of Dextromethorphan/Quinidine (AVP-923) at Two Dosage Levels...
Cariprazine monotherapy shows efficacy against bipolar I disorder
Forest Laboratories and Gedeon Richter have reported preliminary top-line results from a Phase III clinical trial of Cariprazine (RGH-188), an investigational anti-psychotic agent, used to...
EpiCept files fast track status for AmiKet
EpiCept Corporation has filed a fast track designation with the US Food and Drug Administration (FDA) for its AmiKet, used for the treatment of chemotherapy-induced peripheral neuropathy...
